Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome

Schizophrenia Research

Volumn 166, Issue 1-3, 2015, Pages 9-16

  Fervaha, Gagan ^a,b   Foussias, George ^a,b,c   Agid, Ofer ^a,b,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amotivation; Apathy; Avolition; Negative symptoms; Neurocognition; Psychosis; Real world functional outcome; Social functioning

Indexed keywords

ADULT; ALERTNESS; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROBLEM SOLVING; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL SUPPORT; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; COGNITION DISORDERS; CONVALESCENCE; DISEASE COURSE; FOLLOW UP; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REGRESSION ANALYSIS; YOUNG ADULT;

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MOTIVATION; MULTIVARIATE ANALYSIS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RECOVERY OF FUNCTION; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84955189925     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.04.040     Document Type: Article

References (73)

1. Addington, D., Addington, J., Schissel, B., 1990. A depression rating scale for schizophrenics. Schizophr. Res. 3 (4), 247-251.
2. Barch, D.M., Dowd, E.C., 2010. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr. Bull. 36 (5), 919-934.
3. Barch, D.M., Treadway, M.T., Schoen, N., 2014. Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. J. Abnorm. Psychol. 123 (2), 387-397.
4. Barnes, T.R., 1989. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676.
5. Baron, R.M., Kenny, D.A., 1986. Themoderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 51 (6), 1173-1182.
6. Bowie, C.R., Reichenberg, A., Patterson, T.L., Heaton, R.K., Harvey, P.D., 2006. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163 (3), 418-425.
7. Bowie, C.R., Depp, C., McGrath, J.A., Wolyniec, P., Mausbach, B.T., Thornquist, M.H., Luke, J., Patterson, T.L., Harvey, P.D., Pulver, A.E., 2010. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 167 (9), 1116-1124.
8. Chang, W.C., Hui, C.L., Tang, J.Y., Wong, G.H., Lam, M.M., Chan, S.K., Chen, E.Y., 2011. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr. Res. 133 (1-3), 22-28.
9. Choi, K.H., Fiszdon, J.M., Bell, M.D., 2013. Beyond cognition: a longitudinal investigation of the role of motivation during a vocational rehabilitation program. J. Nerv. Ment. Dis. 201 (3), 173-178.
10. Choi, J., Choi, K.H., Felice Reddy, L., Fiszdon, J.M., 2014. Measuring motivation in schizophrenia: is a general state of motivation necessary for task-specific motivation? Schizophr. Res. 153 (1-3), 209-213.
11. Evensen, J., Rossberg, J.I., Barder, H., Haahr, U., Hegelstad, W., Joa, I., Johannessen, J.O., Larsen, T.K., Melle, I., Opjordsmoen, S., Rund, B.R., Simonsen, E., Sundet, K., Vaglum, P., Friis, S., McGlashan, T., 2012. Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophr. Res. 136 (1-3), 19-24.
12. Faerden, A., Nesvag, R., Barrett, E.A., Agartz, I., Finset, A., Friis, S., Rossberg, J.I., Melle, I., 2008. Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis. Eur. Psychiatry 23 (1), 33-39.
13. Faerden, A., Barrett, E.A., Nesvag, R., Friis, S., Finset, A., Marder, S.R., Ventura, J., Andreassen, O.A., Agartz, I., Melle, I., 2013. Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res. 210 (1), 55-61.
14. Fervaha, G., Foussias, G., Agid, O., Remington, G., 2013a. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 210 (2), 665-668.
15. Fervaha, G., Foussias, G., Agid, O., Remington, G., 2013b. Neural substrates of effort computation in schizophrenia. Neurosci. Biobehav. Rev. 37 (10 Pt 2), 2649-2665.
16. Fervaha, G., Graff-Guerrero, A., Zakzanis, K.K., Foussias, G., Agid, O., Remington, G., 2013c. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. J. Psychiatr. Res. 47 (11), 1590-1596.
17. Fervaha, G., Agid, O., Foussias, G., Remington, G., 2014a. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. Schizophr. Res. 152 (1), 317-318.
18. Fervaha, G., Foussias, G., Agid, O., Remington, G., 2014b. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 29 (7), 449-455.
19. Fervaha, G., Foussias, G., Agid, O., Remington, G., 2014c. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr. Scand. 130 (4), 290-299.
20. Fervaha, G., Foussias, G., Siddiqui, I., Agid, O., Remington, G., 2014d. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophr. Res. 154 (1-3), 89-92.
21. Fervaha, G., Takeuchi, H., Lee, J., Foussias, G., Fletcher, P.J., Agid, O., Remington, G., 2015. Antipsychotics and amotivation. Neuropsychopharmacology 40 (6), 1539-1548.
22. First, M.B., 1997. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. Amer Psychiatric Pub Inc., Washington, DC.
23. Foussias, G., Mann, S., Zakzanis, K.K., van Reekum, R., Agid, O., Remington, G., 2011. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr. Res. 132 (1), 24-27.
24. Fulford, D., Niendam, T.A., Floyd, E.G., Carter, C.S., Mathalon, D.H., Vinogradov, S., Stuart, B.K., Loewy, R.L., 2013. Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. Schizophr. Res. 147 (1), 125-131.
25. Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., Rucci, P., Gibertoni, D., Aguglia, E., Amore, M., Bellomo, A., Biondi, M., Brugnoli, R., Dell'Osso, L., De Ronchi, D., Di Emidio, G., Di Giannantonio, M., Fagiolini, A., Marchesi, C., Monteleone, P., Oldani, L., Pinna, F., Roncone, R., Sacchetti, E., Santonastaso, P., Siracusano, A., Vita, A., Zeppegno, P., Maj, M., 2014. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 13 (3), 275-287.
26. Gard, D.E., Fisher, M., Garrett, C., Genevsky, A., Vinogradov, S., 2009. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr. Res. 115 (1), 74-81.
27. Gorissen, M., Sanz, J.C., Schmand, B., 2005. Effort and cognition in schizophrenia patients. Schizophr. Res. 78 (2-3), 199-208.
28. Green, M.F., 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 (3), 321-330.
29. Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26 (1), 119-136.
30. Green, M.F., Hellemann, G., Horan, W.P., Lee, J., Wynn, J.K., 2012. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch. Gen. Psychiatry 69 (12), 1216-1224.
31. Hartmann, M.N., Hager, O.M., Reimann, A.V., Chumbley, J.R., Kirschner, M., Seifritz, E., Tobler, P.N., Kaiser, S., 2015. Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr. Bull. 41 (2), 503-513.
32. Harvey, P.D., 2013. Assessment of everyday functioning in schizophrenia: implications for treatments aimed at negative symptoms. Schizophr. Res. 150 (2-3), 353-355.
33. Harvey, P.D., Raykov, T., Twamley, E.W., Vella, L., Heaton, R.K., Patterson, T.L., 2011. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am. J. Psychiatry 168 (11), 1195-1201.
34. Heinrichs, D.W., Hanlon, T.E., Carpenter Jr., W.T., 1984. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 10 (3), 388-398.
35. Henry, L.P., Amminger, G.P., Harris, M.G., Yuen, H.P., Harrigan, S.M., Prosser, A.L., Schwartz, O.S., Farrelly, S.E., Herrman, H., Jackson, H.J., McGorry, P.D., 2010. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. J. Clin. Psychiatry 71 (6), 716-728.
36. Hunter, R., Barry, S., 2012. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur. Psychiatry 27 (6), 432-436.
37. Jobe, T.H., Harrow, M., 2005. Long-termoutcome of patientswith schizophrenia: a review. Can. J. Psychiatry 50 (14), 892-900.
38. Jones, P.B., Barnes, T.R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., Murray, R.M., Markwick, A., Lewis, S.W., 2006. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63 (10), 1079-1087.
39. Jordan, G., Lutgens, D., Joober, R., Lepage, M., Iyer, S.N., Malla, A., 2014. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J. Clin. Psychiatry 75 (6), e566-e572.
40. Kane, J.M., Schooler, N.R., Marcy, P., Correll, C.U., Brunette, M.F., Mueser, K.T., Rosenheck, R.A., Addington, J., Estroff, S.E., Robinson, J., Penn, D.L., Robinson, D.G., 2015. The RAISE Early Treatment Program for first-episode psychosis: background, rationale, and study design. J. Clin. Psychiatry 76 (3), 240-246.
41. Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (2), 261-276.
42. Keefe, R.S., Mohs, R.C., Bilder, R.M., Harvey, P.D., Green, M.F., Meltzer, H.Y., Gold, J.M., Sano, M., 2003. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 29 (1), 45-55.
43. Keefe, R.S., Bilder, R.M., Harvey, P.D., Davis, S.M., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Miller, D.D., Canive, J.M., Adler, L.W., Manschreck, T.C., Swartz, M., Rosenheck, R., Perkins, D.O., Walker, T.M., Stroup, T.S., McEvoy, J.P., Lieberman, J.A., 2006. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31 (9), 2033-2046.
44. Keefe, R.S., Bilder, R.M., Davis, S.M., Harvey, P.D., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Capuano, G., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Davis, C.E., Hsiao, J.K., Lieberman, J.A., 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64 (6), 633-647.
45. Kerr, S.L., Neale, J.M., 1993. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance? J. Abnorm. Psychol. 102 (2), 312-318.
46. Konstantakopoulos, G., Ploumpidis, D., Oulis, P., Patrikelis, P., Soumani, A., Papadimitriou, G.N., Politis, A.M., 2011. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr. Res. 133 (1-3), 193-198.
47. Leifker, F.R., Patterson, T.L., Heaton, R.K., Harvey, P.D., 2011. Validating measures of realworld outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 37 (2), 334-343.
48. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (12), 1209-1223.
49. Liemburg, E., Castelein, S., Stewart, R., van der Gaag, M., Aleman, A., Knegtering, H., 2013. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J. Psychiatr. Res. 47 (6), 718-725.
50. Lipkovich, I.A., Deberdt, W., Csernansky, J.G., Sabbe, B., Keefe, R.S., Kollack-Walker, S., 2009. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry 9, 44.
51. Marder, S.R., Davis, J.M., Chouinard, G., 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 58 (12), 538-546.
52. Milev, P., Ho, B.C., Arndt, S., Andreasen, N.C., 2005. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal firstepisode study with 7-year follow-up. Am. J. Psychiatry 162 (3), 495-506.
53. Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J.A., Keefe, R.S., 2008. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am. J. Psychiatry 165 (8), 978-987.
54. Nakagami, E., Xie, B., Hoe, M., Brekke, J.S., 2008. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr. Res. 105 (1-3), 95-104.
55. Nakagami, E., Hoe, M., Brekke, J.S., 2010. The prospective relationships among intrinsicmotivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophr. Bull. 36 (5), 935-948.
56. Nuechterlein, K.H., Subotnik, K.L., Green, M.F., Ventura, J., Asarnow, R.F., Gitlin, M.J., Yee, C.M., Gretchen-Doorly, D., Mintz, J., 2011. Neurocognitive predictors ofwork outcome in recent-onset schizophrenia. Schizophr. Bull. 37 (Suppl. 2), S33-S40.
57. Rabinowitz, J., Levine, S.Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C.G., Kapur, S., 2012. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 137 (1-3), 147-150.
58. Ramsay, C.E., Broussard, B., Goulding, S.M., Cristofaro, S., Hall, D., Kaslow, N.J., Killackey, E., Penn, D., Compton, M.T., 2011. Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis. Psychiatry Res. 189 (3), 344-348.
59. Rocca, P., Montemagni, C., Zappia, S., Pitera, R., Sigaudo, M., Bogetto, F., 2014. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting. Psychiatry Res. 218 (3), 284-289.
60. Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J.K., Lieberman, J., 2006. Barriers to employment for people with schizophrenia. Am. J. Psychiatry 163 (3), 411-417.
61. Sabbag, S., Twamley, E.M., Vella, L., Heaton, R.K., Patterson, T.L., Harvey, P.D., 2011. Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr. Res. 131 (1-3), 250-255.
62. Saperstein, A.M., Fiszdon, J.M., Bell, M.D., 2011. Intrinsicmotivation as a predictor of work outcome after vocational rehabilitation in schizophrenia. J. Nerv. Ment. Dis. 199 (9), 672-677.
63. Sayers, S.L., Curran, P.J., Mueser, K.T., 1996. Factor structure and construct validity of the Scale for the Assessment of Negative Symptoms. Psychol. Assess. 8 (3), 269.
64. Shamsi, S., Lau, A., Lencz, T., Burdick, K.E., DeRosse, P., Brenner, R., Lindenmayer, J.P., Malhotra, A.K., 2011. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr. Res. 126 (1-3), 257-264.
65. Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212, 11-19.
66. Strauss, G.P., Horan, W.P., Kirkpatrick, B., Fischer, B.A., Keller, W.R., Miski, P., Buchanan, R.W., Green, M.F., Carpenter Jr., W.T., 2013. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J. Psychiatr. Res. 47 (6), 783-790.
67. Strauss, G.P., Waltz, J.A., Gold, J.M., 2014. A review of reward processing and motivational impairment in schizophrenia. Schizophr. Bull. 40 (Suppl. 2), S107-S116.
68. Stroup, T.S., McEvoy, J.P., Swartz, M.S., Byerly, M.J., Glick, I.D., Canive, J.M., McGee, M.F., Simpson, G.M., Stevens, M.C., Lieberman, J.A., 2003. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 29 (1), 15-31.
69. Swartz, M.S., Perkins, D.O., Stroup, T.S., Davis, S.M., Capuano, G., Rosenheck, R.A., Reimherr, F., McGee, M.F., Keefe, R.S., McEvoy, J.P., Hsiao, J.K., Lieberman, J.A., 2007. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 164 (3), 428-436.
70. Tracy, K., Adler, L.A., Rotrosen, J., Edson, R., Lavori, P., 1997. Interrater reliability issues in multicenter trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol. Bull. 33 (1), 53-57.
71. Ventura, J., Hellemann, G.S., Thames, A.D., Koellner, V., Nuechterlein, K.H., 2009. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 113 (2-3), 189-199.
72. Vohs, J.L., Lysaker, P.H., Nabors, L., 2013. Associations of personality with intrinsic motivation in schizophrenia. Psychiatry Res. 208 (1), 78-80.
73. Yamada, A.M., Lee, K.K., Dinh, T.Q., Barrio, C., Brekke, J.S., 2010. Intrinsic motivation as a mediator of relationships between symptoms and functioning among individuals with schizophrenia spectrum disorders in a diverse urban community. J. Nerv. Ment. Dis. 198 (1), 28-34.